Targeting Urokinase-type plasminogen activator receptor (uPAR) in cancer therapy: Insights from the development of small-molecule inhibitors
- 20 July 2025
- journal article
- review article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 163, 108773
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (22173020)
This publication has 128 references indexed in Scilit:
- Small‐Molecule Inhibition of the uPAR ⋅ uPA Interaction by Conformational SelectionChemMedChem, 2020
- Unconventional Secondary Structure Mimics: Ladder‐RungsAngewandte Chemie International Edition, 2020
- Crystal structure of the unoccupied murine urokinase‐type plasminogen activator receptor (uPAR) reveals a tightly packed DII–DIII unitFEBS Letters, 2019
- Mimicking Intermolecular Interactions of Tight Protein–Protein Complexes for Small‐Molecule AntagonistsChemMedChem, 2017
- Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase ReceptorAngewandte Chemie International Edition, 2016
- Probing Binding and Cellular Activity of Pyrrolidinone and Piperidinone Small Molecules Targeting the Urokinase ReceptorChemMedChem, 2013
- Expression of Urokinase‐Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI‐1) in Human Breast Carcinomas and Their Clinical RelevanceJournal of Clinical Laboratory Analysis, 2012
- What is the relationship between the global structures of apo and holo proteins?Proteins: Structure, Function, and Bioinformatics, 2007
- Variability in the expression of urokinase receptor (CD87) mutants on cells: relevance to cell adhesionCell Biochemistry and Function, 2004
- Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPARStem Cells, 1997